跳至主要内容
临床试验/CTIS2024-516272-14-00
CTIS2024-516272-14-00进行中(未招募)1 期

PRODIG : Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period - N/2015/70

Centre Hospitalier Regional Universitaire0 个研究点目标入组 186 人开始时间: 2024年8月1日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
186

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Patient receiving a first kidney transplant, Patients considered at high risk of developing posttransplant diabetes having at least 2 of the 3 following criteria: Age> 50 years; BMI greater than 30 kg/m²; Direct Family history of type 2 diabetes, Patients who can receive immunosuppressive therapy including tacrolimus, mycophenolic acid and steroids, Patients in whom the cessation of steroids may be considered at the latest at Month 3 post-transplant

排除标准

  • Hepatic insufficiency, Patient with Class IV NYHA Heart Failure, Patient with galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption syndrome, Active infection, Infection with Hepatitis C virus, Multi-Organ Transplantation, A history of diabetes / pancreatitis /angioedema

研究者

发起方
Centre Hospitalier Regional Universitaire

相似试验